Ascendis Pharma posts strong Q3 results, beats earnings and revenue estimates
Ascendis Pharma reported third‑quarter 2026 revenue of about €370 million, up roughly 89% year‑over‑year, driven by sales of YORVIPATH, SKYTROFA and YUVIWEL. Adjusted earnings per share were €1.08, beating the consensus of €0.80. Operating profit rose to €125 million, giving a 34% margin versus 5% a year earlier. The company also announced a share buy‑back of close to two million ordinary shares for roughly $459 million and received positive EU committee opinions for TransCon CNP, with a final decision expected before year‑end and a launch in Germany planned for Q1 2027.
Why it matters
The earnings beat and higher profit margin may support a higher share price, as reflected by the pre‑market rise. The share repurchase signals confidence and reduces outstanding shares, potentially boosting earnings per share. The pending EU approval and planned launch of TransCon CNP could add a new revenue stream later in 2026 and into 2027.
Key facts
- 1Q3 2026 revenue was €369.7 million, up 89% YoY. investing.com
- 2Adjusted EPS was €1.08, beating the €0.80 consensus. investing.com
- 3Operating profit reached €125 million, a 34% margin versus 5% in Q3 2025. investing.com
- 4The company bought back about two million ordinary shares for roughly $459 million through November 11. investing.com
- 5EU committee gave positive opinions for TransCon CNP; final EC decision expected in Q4 2026 and launch in Germany planned for Q1 2027. tradingview.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.